BrainStorm Cell Therapeutics Announces Publication of NurOwn® ALS Phase 2 Randomized Clinical Trial Data in Neurology
November 20, 2019 07:00 ET
|
BrainStorm Cell Therapeutics Inc.
A single transplantation of MSC-NTF cells (NurOwn®) in ALS clinical trial participants met the primary safety endpoint and demonstrated promising stabilization of ALS disease progression of up to...